

# Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia

Richard C. Harvey<sup>1,2</sup> and Sarah K. Tasian<sup>3,4</sup>

<sup>1</sup>Department of Pathology, University of New Mexico School of Medicine, Albuquerque, NM; <sup>2</sup>University of New Mexico Comprehensive Cancer Center, Albuquerque, NM;


<sup>3</sup>Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA; and <sup>4</sup>Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of B-cell acute lymphoblastic leukemia in older children, adolescents, and adults and is associated with high rates of conventional treatment failure and relapse. Current clinical trials are assessing the efficacy of the addition of tyrosine kinase inhibitors (TKIs) to chemotherapy for children and adults with Ph-like ALL harboring ABL class translocations or *CRLF2* rearrangements and other JAK pathway alterations. However, real-time diagnosis of patients can be quite challenging given the genetic heterogeneity of this disease and the often cytogenetically cryptic nature of Ph-like ALL-associated alterations. In this review, we discuss the complex biologic and clinical features of Ph-like ALL across the age spectrum, available diagnostic testing modalities, and current clinical treatment strategies for these high-risk patients. We further propose a practical and step-wise approach to Ph-like ALL genetic testing to facilitate the identification and allocation of patients to appropriate clinical trials of TKI-based therapies or commercially available drugs. Although the majority of patients with Ph-like ALL can be successfully identified via current clinical assays by the end of induction chemotherapy, increasing diagnostic efficiency and sensitivity and decreasing time to test resulting will facilitate earlier therapeutic intervention and may improve clinical outcomes for these high-risk patients.

## Biology and incidence of Ph-like acute lymphoblastic leukemia

The Philadelphia chromosome-like subtype of B-cell acute lymphoblastic leukemia (Ph-like ALL) was initially identified by a characteristic gene expression signature present in patients with very poor clinical outcomes and a high rate of *IKZF1* and other B-cell-associated transcription factor deletions.<sup>1-3</sup> Similarities in these kinase-activated gene-expression patterns to those of patients with *BCR-ABL1*-rearranged (Philadelphia chromosome-positive [Ph<sup>+</sup>]) disease led to this subtype being referred to as “*BCR-ABL1*-like” or “Ph-like,” which is now recognized as a provisional leukemia subtype in the World Health Organization 2016 classification.<sup>4</sup> Although the Ph-like signature itself has been defined somewhat differently by various groups in Europe and North America,<sup>1,2,5-7</sup> these leukemias collectively are now known to be driven by a wide variety of gene fusions, insertions/deletions, and truncations involved in kinase and cytokine signaling potentially targetable with tyrosine kinase inhibitors (TKIs).<sup>8-11</sup>

Over the past decade, the most striking finding in the characterization of Ph-like ALL has been its significant genetic heterogeneity with >70 discrete alterations reported to date.<sup>11-13</sup> The most common kinase fusions are divided into 4 major categories based upon the presumed 3' functional fusion partner: ABL class (*ABL1* [Abelson kinase 1], *ABL2* [Abelson kinase 2]), *CSF1R* [colony-stimulating factor 1 receptor], *PDGFRA* [platelet-derived growth factor A], and *PDGFRB* [platelet-derived growth factor B])



**Figure 1. Relative frequency of Ph-like ALL alterations in children, adolescents, and adults.** Summary data from 5 recent clinical studies (n = 2506 cases) depict the most common ABL class and CRLF2/JAK pathway-associated translocations occurring in children and adults with Ph-like ALL.<sup>8,20,24,44,45</sup>

rearrangements, *CRLF2* (cytokine receptor-like factor 2) rearrangements, *EPOR* [erythropoietin receptor] rearrangements, and *JAK2* rearrangements. The categorization is based upon the similarity of functions of these partners and their potential sensitivity to kinase inhibitors (eg, *SRC/ABL/PDGFR* inhibitors for ABL class fusions<sup>8,14</sup> and JAK inhibitors for *CRLF2*, *EPOR*, and *JAK2* rearrangements<sup>15-18</sup>). Although the frequency of specific Ph-like kinase fusions varies slightly with age, these major subtypes have been reported across the age spectrum and are universally associated with poor clinical outcomes.<sup>8,9,19-25</sup> *CRLF2* rearrangements are most common (64.2%), followed by ABL class (18.7%), *JAK2* (9.0%), and *EPOR* (5.7%) rearrangements (Figure 1). Other rare Ph-like ALL-associated alterations (2.4%) have been reported, such as *SH2B3* deletions potentially targetable by the JAK inhibitor ruxolitinib and *NTRK* fusions potentially targetable by the TRK inhibitors crizotinib and larotrectinib. The continued discovery of new lesions emphasizes the critical importance of unbiased genetic testing that is discussed in greater detail in "Ph-like ALL clinical diagnostics." The spectrum of known Ph-like ALL-associated kinase fusions and their relative frequency in children and adults are listed in Table 1, although these numbers likely slightly underestimate all unique rearrangements, given that several fusions involve different exons of the 5' partner genes. In all of these cases, the resulting oncogenic fusion product is in-frame and retains the functional domains of the 3' partner gene.

The vast majority of these alterations are cytogenetically cryptic and not readily detected by traditional karyotype analysis, which historically made recognition of Ph-like ALL quite challenging or impossible. The advent of more sophisticated RNA-based molecular fusion assays (and DNA-based next-generation sequencing [NGS] analysis) has greatly facilitated identification of Ph-like ALL-associated alterations with significant discovery

of new translocations involving other 5' fusion partners. Although not all methods of identifying fusions are equivalent, a rough estimate of the total number of unique fusions may be approximated by applying Chao estimators for population richness.<sup>26</sup> Based upon the total number of fusions currently identified, the number of those that have been seen exactly once, and the number of those that have been seen exactly twice, an estimate of the probable number of unique fusions may be generated. Application of the Chao 2 estimator to Ph-like ALL yields a predicted value of 192 fusion types if the "Other" category is included and a predicted value of 113 types if only the ABL class, *CRLF2*, *EPOR*, and *JAK2* rearrangements are considered. As more data are generated and fewer singletons are identified, these estimates will likely improve; however, it seems likely that discovery of Ph-like ALL-associated fusions is only about halfway complete.

As mentioned previously, rearrangement of *CRLF2* is the most frequent genetic alteration in Ph-like ALL. *CRLF2* alterations are nearly always accompanied by significantly elevated expression of *CRLF2* transcripts, either by translocation adjacent to the immunoglobulin heavy chain enhancer [t(X;14) or t(Y;14) resulting in *IGH-CRLF2* rearrangement] or by promoter replacement (*P2RY8-CRLF2* fusion from intragenic deletion of the pseudoautosomal region of chromosomes X and Y). It should be noted that 5% to 10% of patients with *CRLF2*-rearranged (*CRLF2*-R) acute lymphoblastic leukemia (ALL; particularly children with National Cancer Institute [NCI] standard risk disease, defined as <10 years old presenting with white blood cell counts <50 000 cells per microliter<sup>27</sup>) have distinctly different gene-expression profiles without the kinase-activated signature and thus are not considered to have Ph-like disease.

Among NCI high-risk (HR) B-precursor ALL (B-ALL) patients (≥10 years of age and/or with diagnostic white blood cell count ≥50 000 cells per microliter<sup>27</sup>) in the United States, the frequency of *IGH-CRLF2* rearrangement appears to be at least twice that of *P2RY8-CRLF2* and increases with age.<sup>20,22-25</sup> This phenomenon has not necessarily been the case in studies outside of the United States; *P2RY8-CRLF2* has been reported to be more common, particularly in children with NCI standard-risk B-ALL who may or may not have the *BCR-ABL1*-like or Ph-like expression signature.<sup>21,28-31</sup> These genetic differences may be attributable in part to the higher prevalence of *CRLF2* rearrangements among patients with HR B-ALL of Hispanic/Latino and Native American ancestry, who are more common in North America; however, these discrepancies remain incompletely elucidated. The *GATA3* single nucleotide polymorphism risk allele rs3824662, which is associated with an increased risk for leukemia relapse, occurs at a higher frequency in patients with Ph-like ALL, particularly those with *CRLF2* rearrangements.<sup>32,33</sup>

Mutations in JAK genes are highly correlated with *CRLF2* rearrangements in Ph-like ALL. Notably, these B-ALL-associated *JAK2* mutations (and, occasionally, *JAK1* mutations) are distinct from the canonical *JAK2* V617F mutation that occurs frequently in adults with myeloproliferative neoplasms.<sup>34</sup> Approximately 40% to 50% of cases of *CRLF2*-R Ph-like ALL harbor pathogenic *JAK2* mutations (most commonly R683G in the pseudokinase domain),<sup>35,36</sup> which almost always occur only in the setting of *CRLF2* rearrangement and have not been seen in conjunction with other

**Table 1. Frequency of kinase fusions in Ph-like ALL**

Active 3' gene	Partner 5' gene	Total number	Boer et al <sup>20</sup>	Imamura et al <sup>44</sup>	Roberts et al <sup>24</sup>	Roberts et al <sup>8</sup>	Reshmi et al <sup>45</sup>
ABL1	CENPC	1	—	—	—	—	1
	ETV6	7	—	1	2	2	2
	FOXP1	1	1	—	—	—	—
	LSM14A	1	—	—	—	—	1
	NUP153	1	—	—	—	—	1
	NUP214	12	—	—	1	6	5
	RANBP2	4	—	—	—	1	3
	RCSD1	3	—	—	1	1	1
	SFPQ	1	—	—	1	—	—
	SNX1	1	—	1	—	—	—
	SNX2	2	—	—	1	1	—
	ZMIZ1	7	1	1	—	2	3
	ABL2	PAG1	2	—	—	1	1
RCSD1		8	1	—	2	3	2
ZC3HAV1		6	—	—	3	1	2
CSF1R	MEF2D	1	—	—	1	—	—
	SSBP2	9	2	—	—	4	3
	TBL1XR1	1	—	—	—	—	1
PDGFRA	FIP1L1	1	—	—	1	—	—
PDGFRB	ATF7IP	3	—	2	—	—	1
	EBF1	28	4	6	3	6	9
	ETV6	1	—	—	—	—	1
	SNX29	1	—	—	1	—	—
	SSBP2	1	—	—	—	1	—
	TNIP1	3	—	—	—	—	3
	ZEB2	1	—	—	—	1	—
	ZMYND8	1	—	—	—	—	1
JAK2	ATF7IP	3	—	—	2	1	—
	BCR	7	1	—	1	2	3
	EBF1	1	—	—	—	1	—
	ETV6	3	—	—	1	1	1
	OFD1	1	—	1	—	—	—
	PAX5	19	3	1	5	6	4
	PCM1	1	—	—	—	—	1
	PPFIBP1	2	—	—	1	1	—
	RFX3	1	—	—	—	—	1
	SMU1	1	—	—	1	—	—
	SSBP2	6	—	—	2	2	2
	STRN3	1	—	—	—	1	—
	TERF2	2	1	—	—	1	—
	TPR	1	—	—	—	1	—
USP25	1	—	—	—	—	1	
EPOR	IGH	29	—	3	8	7	11
	IGK	3	—	—	1	2	—
	THADA	1	—	—	1	—	—

Data are summarized from 5 recent studies of 2506 pediatric and adult patients with B-ALL.

Downloaded from <http://ashpublications.net/bloodadvances/article-pdf/4/1/218/1552119/advancesadv2019000163c.pdf> by guest on 08 June 2024

**Table 1. (continued)**

Active 3' gene	Partner 5' gene	Total number	Boer et al <sup>20</sup>	Imamura et al <sup>44</sup>	Roberts et al <sup>24</sup>	Roberts et al <sup>6</sup>	Reshmi et al <sup>45</sup>
<i>CRLF2</i>	<i>IGH</i>	181	—	2	57	61	61
	<i>P2RY8</i>	149	8	10	22	45	64
	Unknown	41	4	—	20	17	—
<i>BLNK</i>	<i>DNTT</i>	1	—	—	1	—	—
<i>CBL</i>	<i>KANK1</i>	1	—	—	1	—	—
<i>DGKH</i>	<i>ZFAND3</i>	1	—	—	—	1	—
<i>FLT3</i>	<i>ZMYM2</i>	1	—	—	1	—	—
<i>IL2RB</i>	<i>MYH9</i>	1	—	—	—	1	—
<i>LYN</i>	<i>GATA2DA</i>	1	—	—	—	—	1
	<i>NCOR1</i>	1	—	1	—	—	—
<i>NTRK3</i>	<i>ETV6</i>	3	—	—	1	1	1
<i>PTK2B</i>	<i>TMEM2</i>	1	—	—	1	—	—
<i>TYK2</i>	<i>MYB</i>	1	—	—	—	1	—
	<i>SMARCA4</i>	1	—	—	1	—	—
	<i>ZNF340</i>	1	—	—	1	—	—
Total		578					

Data are summarized from 5 recent studies of 2506 pediatric and adult patients with B-ALL.

Ph-like alterations. Interestingly, ~50% to 60% of children with Down syndrome–associated ALL have *CRLF2* rearrangements (usually *P2RY8-CRLF2* fusions) and *JAK2* R683G mutations.<sup>31,37-42</sup> The frequency of the Ph-like ALL expression signature among patients with *CRLF2*-R Down syndrome–associated ALL has not been determined.

Some patients with *CRLF2*-R Ph-like ALL have concomitant *IL7R* (interleukin-7 receptor) insertions and deletions (indels), which appear to be mutually exclusive from *CRLF2*-R cases with *JAK2* or *JAK1* mutations.<sup>8,43</sup> Among the 2506 patients with B-ALL in the 5-study summary analysis in Figure 1,<sup>8,20,24,44,45</sup> 80.8% of identified *IL7R* indels occurred in patients with the Ph-like subtype (4.3% of all Ph-like patients). It is difficult to estimate the true frequency of *IL7R* indels in Ph-like ALL because not all studies performed *IL7R* mutation analysis. Beyond Ph-like ALL, *IL7R* indels have been reported in 5% to 10% of patients with T-ALL,<sup>46</sup> and *JAK1* and *JAK3* point mutations (but not *JAK2*) are also relatively common in T-ALL.<sup>47-49</sup>

Finally, mutations in *NRAS*, *KRAS*, *PTPN11*, *NF1*, *BRAF*, and *FLT3* have been detected in a small number of patients with Ph-like ALL. Many of these (usually subclonal) Ras pathway mutations arise in conjunction with sentinel Ph-like translocations (eg, ABL class, *CRLF2*, *EPOR*, or *JAK2* fusions), whereas other mutations appear to occur in isolation.<sup>8,9</sup> It is plausible that these mutations could be targeted with MEK or FLT3 inhibitors,<sup>50-53</sup> but such strategies have not been formally evaluated in patients with Ph-like ALL.


## Ph-like ALL clinical diagnostics

### Gene-expression analyses

The first Ph-like classifier was developed over a decade ago by Den Boer and colleagues at Erasmus University and in the Dutch Children's Oncology Group and used a panel of 110 genes.

Hierarchical clustering of the associated probe set expression levels proved highly accurate in separating childhood ALL specimens into 6 distinct categories, including a newly described “*BCR-ABL1*-like” subtype with a kinase-activated signature very similar to that of Ph<sup>+</sup> ALL.<sup>9</sup> Two research predictors of the Ph-like ALL expression signature were also developed during this time by researchers in the North America–based Children's Oncology Group (COG): (1) a predictive analysis of microarrays at the St. Jude Children's Research Hospital (SJCRH) and (2) a low-density microarray (LDA) analysis at the University of New Mexico.<sup>54,55</sup> These 2 modalities have yielded very similar Ph-like ALL classifications of diagnostic SJCRH and COG ALL specimens, although they appear to have somewhat less concordance with methodologies developed in European studies; the discrepancies may be influenced, in part, by the differing ethnic populations in North America vs Europe.<sup>21</sup> Although predictive analysis of microarrays and LDA predictors use a continuous scale and apply cutoffs for determining the binary classification of Ph-like or not, the scores themselves are informative about the likelihood of certain fusions.

Figure 2 shows results from cumulative LDA analyses of 2506 HR B-ALL patient specimens analyzed in 5 large studies.<sup>8,20,24,44,45</sup> Using the now clinically validated 8- or 15-gene (*IGJ*, *SPATS2L*, *MUC4*, *CRLF2*, *CA6*, *NRXN3*, *BMPR1B*, *GPR110*, *CHN2*, *SEMA6A*, *PON2*, *SLC2A5*, *S100Z*, *TP53INP1*, *IFITM1*) LDA predictor threshold  $\geq 0.5$  (range, 0-1) to define a positive Ph-like signature,<sup>5</sup> the majority of ABL class (93.9%), *EPOR* (100%), and *JAK2* (96.3%) fusion events are associated with scores  $\geq 0.7$ . Most Ph-like *CRLF2*-R ALL cases (87.6%) also have scores  $\geq 0.7$ . The LDA predictor has largely been used by the COG and other cooperative groups as a cost-effective rapid clinical screening tool to determine which HR B-ALL cases require further specific Ph-like molecular characterization for potential clinical trial participation (~20%) and which do not (~80%). A high LDA score can provide a rapid index of suspicion within 48 hours of diagnostic sample receipt



**Figure 2. Occurrence of Ph-like ALL fusions and correlation with 15-gene LDA predictor score.** Distribution of childhood and adult Ph-like ALL cases by 15-gene LDA score and specific Ph-like gene rearrangement.<sup>8,24,45</sup> LDA scores  $\geq 0.5$  are considered positive for the Ph-like ALL expression signature. The majority of Ph-like cases have LDA scores  $\geq 0.85$ , particularly those with ABL class, *JAK2*, and *EPOR* rearrangements. Some *CRLF2-R* cases have lower LDA scores in the 0.5 to 0.8 range.

regarding the likelihood of Ph-like kinase fusions and can alert treating physicians that TKI addition to chemotherapy may be appropriate for a patient if more detailed testing confirms relevant genetic alterations.

### Cytogenetics and fluorescence in situ hybridization

Conventional cytogenetics analysis and fluorescence in situ hybridization (FISH) studies are routinely performed in the diagnostic evaluation of patients with newly diagnosed ALL; results are usually available in 7 to 10 days. Although karyotypic analysis can identify major structural alterations [eg, t(9;22) resulting in *BCR-ABL1* rearrangement in Ph<sup>+</sup> ALL], the majority of Ph-like ALL-associated alterations are cytogenetically cryptic. However, clinical break-apart FISH probes have been developed for many of the 3' genes commonly involved in Ph-like ALL translocations, including *ABL1*, *ABL2*, *CRLF2*, *EPOR*, *JAK2*, and *PDGFRB* (this probe often also detects *CSF1R*), with rapid result return often within 3 or 4 days. Although FISH analysis often cannot identify the specific 5' fusion gene partner, abnormal 3' gene results can provide the first clinical suspicion for ABL class or *CRLF2-R/JAK* pathway-mutant Ph-like ALL and allocate patients efficiently who require further molecular characterization. Ostensibly, clinical FISH testing with results return within 7 to 10 days of leukemia diagnosis could facilitate earlier therapeutic intervention with JAK inhibitor or ABL/PDGFR inhibitor addition early in induction chemotherapy (as is done for patients with Ph<sup>+</sup> ALL<sup>56-58</sup> [and NCT03007147]) while completing more detailed molecular analysis to delineate the specific Ph-like rearrangement.

### RT-PCR and polymerase chain reaction analyses

Molecular characterization of specific Ph-like ALL kinase fusions can be rapidly accomplished using RNA/complementary DNA-based reverse-transcriptase polymerase chain reaction (RT-PCR) analyses. These targeted assays have a turn-around time of as little as 2 to 3 days and can be "multiplexed" with capabilities for simultaneous testing of multiple kinase fusions. Multiplexed RT-PCR

of 39 known Ph-like fusions was an initial approach used by the COG and other consortia for molecular characterization of Ph-like alterations in LDA<sup>+</sup> ALL specimens.<sup>9,11</sup> However, these RT-PCR assays had significant "false-negative" potential because 5' and 3' genes and breakpoints must be known a priori; thus, these assays were often unable to identify kinase fusions with promiscuous breakpoints or previously unknown 5' partners.<sup>18</sup>

DNA-based polymerase chain reaction (PCR) assays have been very useful in the detection of common Ph-like ALL-associated mutations, including *JAK2* and *JAK1* point mutations<sup>35,36</sup> and *IL7R* indels.<sup>43</sup> Rarely, *CRLF2* F232C point mutations occur in *CRLF2*-overexpressing ALL cases<sup>59,60</sup>; these mutations seem to be largely independent of the *IGH-CRLF2* and *P2RY8-CRLF2* rearrangements and can be easily discovered by PCR. Confirmatory clinical Sanger sequencing of all PCR-detected fusions, point mutations, and indels is recommended.

### Flow cytometric immunophenotyping

Increased surface thymic stromal lymphopoietin receptor (TSLPR; encoded by *CRLF2*) staining of ALL blasts, which is readily detectable by flow cytometry, has proven to be highly predictive of *IGH-CRLF2* and *P2RY8-CRLF2* rearrangements and *CRLF2* F232 point mutations in primary Ph-like ALL cells.<sup>15</sup> Clinical TSLPR immunophenotyping (now performed as part of routine diagnostic flow cytometry panels<sup>23</sup>) is highly cost effective and can identify patients with probable *CRLF2-R* B-ALL within 24 hours of specimen acquisition. Several institutions are now routinely incorporating TSLPR flow cytometry into their diagnostic ALL evaluations and/or using it for potential clinical trial screening (M.Y. Konopleva, MD Anderson Cancer Center [MDACC], personal communication; M.J. Borowitz, Johns Hopkins University, personal communication). Confirmatory genetic testing of TSLPR<sup>+</sup> specimens by FISH, fusion analysis (described in detail in "NGS platforms"), and/or RT-PCR should be performed to characterize the specific *CRLF2* alterations as well as potential JAK and *IL7R* mutations by PCR analysis, if desired.



## NGS platforms

Several commercial and institutional laboratories now offer RNA- and DNA-based hybrid capture or anchored multiplex PCR-based assays for Ph-like ALL characterization, most of which are quite capable of identifying new fusions. Because these assays have become more widely available and cost effective, many institutions and cooperative groups have shifted testing from multiplexed RT-PCR panels to these more comprehensive methodologies. Although some methods for fusion identification are restricted to known gene partners, a more generic approach that also permits discovery of new fusions relies upon priming of the presumed functional 3' gene partner and extending through the 5' fusion partners, whether known or novel. The FoundationOne Heme panel is a targeted combined RNA and DNA sequencing method capable of fusion and mutation detection in >400 cancer-related genes.<sup>61</sup> The NanoString nCounter digital molecular barcoding platform can identify >200 known leukemia-associated oncogenic fusions.<sup>62</sup> The ArcherDX FusionPlex Heme panel is an example of the more generic fusion detection approach; it uses capture-based chemistry that targets 87 hematologic malignancy-associated genes while remaining agnostic to the 5' fusion partner,<sup>63</sup> thereby facilitating potential discovery of novel fusions. All of these platforms require ~2 to 4 weeks for clinical result reporting, although they have appreciable advantages of more comprehensive and informative analyses.

## Whole-exome, transcriptome, and genome sequencing

Rarely, kinase fusions or other Ph-like mutations are not identified in clearly LDA<sup>+</sup> ALL specimens. Research-level transcriptomic/RNA sequencing (RNAseq) has been performed on some of these specimens and identified previously unknown alterations that are probable oncogenic drivers in Ph-like ALL.<sup>18</sup> Clinical RNAseq is becoming increasingly available and will likely augment or replace current diagnostic targeted testing platforms, although this approach remains quite costly and with relatively slower turnaround time given the complex bioinformatics analysis required. RNAseq analysis can be further complicated by the fact that many fusions are expressed at very low levels, and the fidelity and depth of the sequencing are paramount in being able to distinguish low-level fusions from sequencing artifacts. Whole-exome sequencing was previously used in the initial characterization of Ph-like ALL<sup>64</sup> and is useful for point mutation and indel detection, but it generally misses fusions that involve areas outside of coding regions. Whole-genome sequencing (WGS) is another useful technique for characterizing Ph-like ALL, but is currently largely performed only at the research level given its high cost and prolonged timing for test resulting. Although WGS is capable of identifying genomic rearrangements, mutations, and indels, it is incapable of demonstrating that a rearrangement results in a coding fusion or altered transcript that must be identified via RNAseq.

## Clinical implementation of Ph-like ALL screening: an example of the current COG approach

LDA screening of all pediatric and adolescent and young adult (AYA) patients with HR B-ALL has been broadly implemented by the COG and used by other consortia to efficiently identify patients with Ph-like ALL who merit additional detailed genetic testing and may be eligible for clinical trials testing relevant TKIs with

chemotherapy.<sup>11</sup> In practice, LDA results have been returned within 48 to 72 hours, allowing rapid "ruling out" of the 70% to 80% of non-Ph-like ALL patients ("LDA<sup>-</sup>") and triggering further genetic testing recommendations for patients with LDA positivity. Of note, the LDA assay also detects specimens with *BCR-ABL1* and *ETV6-RUNX1* rearrangements due to similarities in expression signatures; accordingly, such patients are not allocated for further testing. In the COG workflow, specimens identified as Ph-like are initially triaged based upon the level of *CRLF2* expression (high or low) assessed by LDA, including direct identification of potential *P2RY8-CRLF2* fusions in *CRLF2*-overexpressing specimens. Ph-like specimens with high *CRLF2* expression that test negative for the *P2RY8-CRLF2* fusion by LDA are then assessed for *IGH-CRLF2* translocations by FISH assays, with results returned in 1 week. All *CRLF2*-R samples are further subjected to *JAK1*, *JAK2*, and *IL7R* PCR mutation analysis that usually also requires 1 week for resulting. LDA<sup>+</sup> specimens with normal *CRLF2* expression are sent for customized Archer-based kinase fusion testing to assess for *JAK2*, *EPOR*, and *ABL* class rearrangements and other rare Ph-like-associated alterations, with a current turnaround time ~ 3 weeks.<sup>11</sup> As above, clinical RNAseq analysis can be performed for specimens with the Ph-like expression signature in which no kinase fusion or other oncogenic mutation is identified, but this testing often requires 4 to 8 weeks to result and is generally too slow to allow allocation of relevant patients to TKI-based clinical trials that begin at the consolidation phase of therapy.

## Current clinical trials for patients with Ph-like ALL

Addition of ABL-targeting TKIs to chemotherapy for patients with Ph<sup>+</sup> ALL has markedly improved relapse-free and overall survival and provides an important precision medicine paradigm for other HR leukemia subtypes.<sup>56-58,65-67</sup> Analogous approaches for patients with Ph-like ALL are under investigation given similar activated kinase expression profiles and kinase gene fusions that can also be targeted with small molecule inhibitors. The majority of Ph-like ALL cases can be "binned" into 2 classes for therapeutic targeting purposes: ABL class mutant (including *ABL1*, *ABL2*, *CSF1R*, and *PDGFRB* rearrangements) and JAK pathway mutant (including *CRLF2*, *JAK2*, or *EPOR* rearrangements, *SH2B3* deletions, and *IL7R* indels). As described in detail in "ABL class alterations" and "CRLF2 rearrangements and other JAK pathway alterations," several clinical trials are investigating whether addition of the SRC/ABL/PDGFRB inhibitor dasatinib or the JAK1/2 inhibitor ruxolitinib to multiagent backbone chemotherapy can improve the known poor clinical outcomes of children and adults with Ph-like ALL (Table 2).

## ABL class alterations

Several groups have reported potent activity of imatinib or dasatinib in vitro and in vivo in ABL class-mutant Ph-like ALL cells and patient-derived xenograft models.<sup>8,14,25</sup> Anecdotal case reports have further demonstrated clinical efficacy of combining these TKIs with chemotherapy in children and AYAs with chemotherapy-refractory B-ALL with *PDGFRB*, *ABL1*, or *ABL2* fusions.<sup>8,68-70</sup> Imatinib, dasatinib, and later-generation TKIs are approved by the US Food and Drug Administration and European Medicines Agency for adults and children with chronic myeloid leukemia or Ph<sup>+</sup> ALL, but have not been approved for patients with Ph-like ALL. Multiple

**Table 2. Current clinical trials of kinase inhibitor therapies for children and adults with Ph-like ALL**

Ph-like alteration	Kinase inhibitor	Disease status	Age, y	Clinical trial	Trial phase
ABL class	Dasatinib	Newly diagnosed	1-30	NCT01406756 (COG AALL1131)	3 (dasatinib subarm)
	Dasatinib	Newly diagnosed	1-18	NCT03117751 (SJCRH Total XVII)	3 (dasatinib subarm)
	Dasatinib	Relapsed	≥10	NCT02420717 (MDACC)	1/2
CRLF2/JAK pathway	Ruxolitinib	Newly diagnosed	1-21	NCT02723994 (COG AALL1521)	2
	Ruxolitinib	Newly diagnosed	1-18	NCT03117751 (SJCRH Total XVII)	3 (ruxolitinib subarm)
	Ruxolitinib	Newly diagnosed	18-39	NCT03571321	1 (planned phase 2 expansion)
	Ruxolitinib	Relapsed	≥10	NCT02420717 (MDACC)	1/2

clinical trials are now studying nonrandomized addition of dasatinib to chemotherapy in patients with relapsed or newly diagnosed ABL class-mutant Ph-like ALL (Table 2). A phase 1/2 study conducted at MDACC is testing the safety and potential efficacy of dasatinib with hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) chemotherapy in adolescents and adults with relapsed/refractory Ph-like ALL and ABL class fusions (NCT02420717); interim data analysis demonstrated safety of combination therapy without identified dose-limiting toxicity.<sup>71</sup> The potential efficacy of dasatinib and postinduction chemotherapy in children and AYAs with de novo ABL class-mutant Ph-like ALL has been studied descriptively on arms of the phase 3 COG AALL1131 (NCT01406756) and the SJCRH Total XVII (NCT03117751) trials, with comparison with historic control data from Ph-like patients treated with chemotherapy alone. These up-front TKI addition approaches aim to decrease relapse risk and to improve overall survival in children and AYAs with Ph-like ALL, as has been observed in patients with Ph<sup>+</sup> ALL treated with imatinib or dasatinib. Although anecdotal case reports have described responses of patients with ABL class Ph-like ALL to imatinib or dasatinib,<sup>8,68,69</sup> results from these larger clinical trials are not yet known.

### CRLF2 rearrangements and other JAK pathway alterations

Preclinical studies have also shown appreciable activity of JAK inhibitors *in vitro* and *in vivo* in *CRLF2*-R and other JAK pathway-mutant Ph-like ALL cell lines and patient-derived xenograft models.<sup>16-18,72-74</sup> Although several JAK inhibitors have been studied in patients with autoimmune diseases and hematologic malignancies,<sup>75,76</sup> ruxolitinib (a selective JAK1/JAK2 inhibitor<sup>77</sup>) has been most widely studied in ALL. Ruxolitinib is approved by the US Food and Drug Administration and European Medicines Agency for treatment of adults with myelofibrosis and polycythemia vera (usually harboring somatic *JAK2* V617F mutations), but it is not approved for use in children or in patients with acute leukemias. The COG ADVL1011 phase 1 trial established the safety and recommended phase 2 dose of ruxolitinib in pediatric patients (1-21 years of age) with relapsed/refractory solid tumors and hematologic malignancies. A maximally tolerated dose of ruxolitinib and major dose-limiting toxicities were not identified in this study.<sup>78</sup>

The aforementioned MDACC Ph-like ALL phase 1/2 trial (NCT02420717) also tested low-dose ruxolitinib with hyper-CVAD chemotherapy for adolescents and adults with relapsed/refractory *CRLF2*-R/JAK-mutant ALL. Combination therapy was well tolerated, but limited efficacy was observed.<sup>71</sup> Similar to the AALL1131 dasatinib arm for patients with ABL class alterations, the COG is also testing the safety and efficacy of ruxolitinib addition to


chemotherapy in children and AYAs with newly diagnosed Ph-like ALL and *CRLF2* rearrangements or other JAK pathway alterations via the single-arm AALL1521 phase 2 trial (NCT02723994). Patients are stratified into 4 cohorts by Ph-like genetic alterations (*CRLF2*-R, *CRLF2*-R with JAK mutation, other JAK pathway lesions) and by end-induction minimal residual disease status (≥0.01 or <0.01% by flow cytometry) to allow for the more precise study of potential efficacy differences among these subgroups. Safety data for ruxolitinib with postinduction chemotherapy from part 1 of this trial were recently reported, and no dose-limiting toxicity of combination therapy was identified.<sup>79</sup> Part 2 of AALL1521 is currently assessing the efficacy of ruxolitinib with chemotherapy and will compare outcomes with those of patients treated with chemotherapy alone on the prior COG AALL0232 phase 3 trial (NCT00075725).<sup>80</sup> The SJCRH Total XVII trial is also assessing the safety and potential efficacy of ruxolitinib with chemotherapy in children with de novo *CRLF2*-R/JAK pathway-mutant Ph-like ALL (NCT03117751). Finally, a recently opened phase 1 trial at the University of Chicago and other institutions (NCT03571321) is studying ruxolitinib in combination with the pediatric-inspired CALBG 10403 chemotherapy regimen (NCT00558519)<sup>81,82</sup> specifically in AYA patients (18-39 years of age) with newly diagnosed Ph-like ALL with a planned phase 2 expansion if safety is demonstrated.

### Conclusions and diagnostic recommendations

Ph-like ALL is a common leukemia subtype in children and adults that is associated with high rates of chemotherapy resistance and relapse. Historically, clinical diagnosis of patients with Ph-like ALL has proven quite challenging given the now-known significant genetic heterogeneity of associated kinase fusions that are often cytogenetically cryptic and that previously required lengthy step-wise and costly testing that, nonetheless, failed to identify many lesions. Sophisticated RNA-based testing platforms (many of which are far more capable of new fusion partner discovery) that are now widely clinically available have appreciably facilitated identification of patients with Ph-like ALL and their specific leukemia-associated fusions, but these approaches require several weeks for data resulting. Instead, routine clinical FISH testing with the use of new *ABL1*, *ABL2*, *CRLF2*, *JAK2*, and *PDGFRB* probes and flow cytometric immunophenotyping for increased TSLPR surface expression may provide early suspicion for Ph-like ALL in relevant patients. Such approaches could be used for early intervention with appropriate TKI addition to chemotherapy while awaiting specific Ph-like ALL molecular analysis by more detailed testing.

Based upon these scientific and clinical advances, we propose a practical, cost-effective, and time-efficient clinical algorithm to identify patients with Ph-like ALL (Figure 3). All pediatric patients

**Figure 3. Recommended clinical testing algorithm for identification of patients with Ph-like ALL.**



with NCI HR B-ALL and adult patients with B-ALL should undergo routine diagnostic flow cytometric immunophenotyping with a panel that includes an anti-TSLPR (CRLF2) antibody.<sup>15,83</sup> All patients should also undergo routine cytogenetics and FISH analysis using *ABL1*, *ABL2*, *CRLF2*, *EPOR*, *JAK2*, and *PDGFRB* probes that can rapidly identify probable Ph-like ALL in specimens with detected aberrant signals. Leukemia specimens with identified increased flow cytometric TSLPR staining should be specifically allocated for *CRLF2* FISH, particularly in the AYA population, in which *IGH-CRLF2* translocations are more common.<sup>84</sup> TSLPR<sup>+</sup> specimens with negative *CRLF2* rearrangement FISH data should be sent for *P2RY8-CRLF2* fusion analysis via RT-PCR or fusion panel testing. For complete genetic characterization, *CRLF2-R* specimens can also be tested via targeted PCR or more comprehensive NGS to assess potential *JAK1* and *JAK2* mutations, *IL7R* indels, and associated transcription factor deletions (eg, *IKZF1*, *CDKN2A*, *CDKN2B*, *PAX5*<sup>3</sup>) that are common in Ph-like ALL and may further contribute to prognosis.

We maintain that adult and HR pediatric B-ALL specimens with normal (nonincreased) TSLPR staining that lack canonical leukemia-associated alterations (eg, *BCR-ABL1*, *ETV6-RUNX1*, hyperdiploidy, hypodiploidy, *iAMP21*, *KMT2A* rearrangements, *TCF3-PBX1*, *TCF3-HLF*) should be sent for comprehensive fusion panel testing and NGS analysis. These testing platforms have rapidly become more affordable and with shorter “turnaround time” for resulting, and the potential discovery of Ph-like (and non-Ph-like) translocations and mutations could have major prognostic and therapeutic implications for patients. It is also plausible that clinical RNAseq analysis will become more widely available and affordable in the near future with more rapid return of results, and such testing may eventually replace targeted cancer fusion and NGS panels. Finally, we propose that LDA analysis remains a helpful screening tool to “rule out” the large number of non-Ph-like cases and to triage selected Ph-like cases for downstream molecular analysis, particularly in the younger pediatric population and those with *P2RY8-CRLF2* fusions. Conversely, we suggest that LDA is probably unnecessary for AYA and older patients and those with ABL class, *JAK2*, *EPOR*, and *IGH-CRLF2* rearrangements that can be readily detected by FISH and fusion analyses and are now well known to be near-universally

associated with the Ph-like expression signature and poor clinical outcomes with conventional therapy.

In summary, several clinical trials of dasatinib and ruxolitinib with multiagent chemotherapy are in progress for patients with ABL class-mutant and *CRLF2-R/JAK* pathway-mutant Ph-like ALL, respectively, but the impact of these interventions upon relapse-free and overall survival is not yet known. Given the remarkable success and clinical tolerability of CD19- and CD22-targeted antibody-based and cellular immunotherapies in patients with relapsed/refractory B-ALL, evaluation of the potential efficacy of combining TKIs with immunotherapy could also be considered in future Ph-like ALL clinical trials. Further refinement of Ph-like ALL testing methodologies with more rapid test resulting will continue to facilitate the swift identification of these extremely HR patients who may benefit from alternative therapeutic approaches and clinical trials.

## Acknowledgments

R.C.H. was supported by National Institutes of Health, National Cancer Institute grants R50CA211542 and P30CA118100. S.K.T. was supported by National Institutes of Health, National Cancer Institute grants K08CA18441 and 1U01CA232486; Department of Defense grant CA180683P1; and the Rally Foundation for Childhood Cancer Research.

## Authorship

Contribution: R.C.H. and S.K.T. wrote the manuscript.

Conflict-of-interest disclosure: R.C.H. is an inventor on US Patent 8568974 relating to the use of gene-expression signatures to identify Ph-like patients, but receives no royalties. S.K.T. receives research funding from Incyte Corporation.

ORCID profiles: R.C.H., 0000-0002-4904-9767; S.K.T., 0000-0003-1327-1662.

Correspondence: Sarah K. Tasian, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, 3501 Civic Center Blvd, CTRB 3010, Philadelphia, PA 19104; e-mail: tasians@email.chop.edu.



## References

1. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. *Blood*. 2010;116(23):4874-4884.
2. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. *Lancet Oncol*. 2009;10(2):125-134.
3. Stanulla M, Dagdan E, Zaliova M, et al; International BFM Study Group. IKZF1<sup>plus</sup> defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. *J Clin Oncol*. 2018;36(12):1240-1249.
4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in *Blood*. 2016;128(3):462-463]. *Blood*. 2016;127(20):2391-2405.
5. Harvey RC, Kang H, Roberts KG, et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like ("Ph-like" or "BCR-ABL1-Like") signature for therapeutic targeting and clinical intervention. *Blood*. 2013;122(21):826.
6. Haferlach T, Kohlmann A, Schnittger S, et al. Global approach to the diagnosis of leukemia using gene expression profiling. *Blood*. 2005;106(4):1189-1198.
7. Chiaretti S, Li X, Gentleman R, et al. Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. *Clin Cancer Res*. 2005;11(20):7209-7219.
8. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *N Engl J Med*. 2014;371(11):1005-1015.
9. Roberts KG, Reshmi SC, Harvey RC, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. *Blood*. 2018;132(8):815-824.
10. Boer JM, Steeghs EM, Marchante JR, et al. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia. *Oncotarget*. 2017;8(3):4618-4628.
11. Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia. *Blood*. 2017;130(19):2064-2072.
12. Roberts KG. Why and how to treat Ph-like ALL? *Best Pract Res Clin Haematol*. 2018;31(4):351-356.
13. Chiaretti S, Messina M, Foà R. BCR/ABL1-like acute lymphoblastic leukemia: how to diagnose and treat? *Cancer*. 2019;125(2):194-204.
14. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell*. 2012;22(2):153-166.
15. Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. *Blood*. 2012;120(4):833-842.
16. Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. *Blood*. 2012;120(17):3510-3518.
17. Iacobucci I, Li Y, Roberts KG, et al. Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. *Cancer Cell*. 2016;29(2):186-200.
18. Ding YY, Stern JW, Jubelirer TF, et al. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with *GOLGA5-JAK2* fusion and induction failure. *Haematologica*. 2018;103(9):e427-e431.
19. Heatley SL, Sadras T, Kok CH, et al. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. *Haematologica*. 2017;102(12):e490-e493.
20. Boer JM, Koenders JE, van der Holt B, et al. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates. *Haematologica*. 2015;100(7):e261-e264.
21. Boer JM, Marchante JR, Evans WE, et al. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. *Haematologica*. 2015;100(9):e354-e357.
22. Herold T, Schneider S, Metzeler KH, et al. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. *Haematologica*. 2017;102(1):130-138.
23. Jain N, Roberts KG, Jabbour E, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. *Blood*. 2017;129(5):572-581.
24. Roberts KG, Gu Z, Payne-Turner D, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. *J Clin Oncol*. 2017;35(4):394-401.
25. Tasian SK, Hurtz C, Wertheim GB, et al. High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL. *Leukemia*. 2017;31(4):981-984.
26. Chao A. Estimating the population size for capture-recapture data with unequal catchability. *Biometrics*. 1987;43(4):783-791.
27. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. *J Clin Oncol*. 1996;14(1):18-24.
28. Ensor HM, Schwab C, Russell LJ, et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. *Blood*. 2011;117(7):2129-2136.
29. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. *Blood*. 2010;115(26):5312-5321.

30. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. *Nat Genet.* 2009;41(11):1243-1246.
31. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. *Blood.* 2009;114(13):2688-2698.
32. Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. *Nat Genet.* 2013;45(12):1494-1498.
33. Jain N, Zhang H, Roberts KG, et al. GATA3 rs3824662A allele is overrepresented in adult patients with Ph-like ALL, especially in patients with CRLF2 abnormalities. *Blood.* 2017;130(suppl 1):1430.
34. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell.* 2005;7(4):387-397.
35. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. *Proc Natl Acad Sci USA.* 2009;106(23):9414-9418.
36. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. *Lancet.* 2008;372(9648):1484-1492.
37. Gaikwad A, Rye CL, Devidas M, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. *Br J Haematol.* 2009;144(6):930-932.
38. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. *Blood.* 2010;115(5):1006-1017.
39. Schwartzman O, Savino AM, Gombert M, et al. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. *Proc Natl Acad Sci USA.* 2017;114(20):E4030-E4039.
40. Buitenkamp TD, Pieters R, Gallimore NE, et al. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. *Leukemia.* 2012;26(10):2204-2211.
41. Russell LJ, Jones L, Enshaei A, et al. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. *Genes Chromosomes Cancer.* 2017;56(5):363-372.
42. Potter N, Jones L, Blair H, et al. Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia. *Leukemia.* 2019;33(4):893-904.
43. Shochat C, Tal N, Bandapalli OR, et al. Gain-of-function mutations in interleukin-7 receptor- $\alpha$  (IL7R) in childhood acute lymphoblastic leukemias [published corrections appear in *J Exp Med.* 2011;208(6):1333; *J Exp Med.* 2011;208(5):preceding 901]. *J Exp Med.* 2011;208(5):901-908.
44. Imamura T, Kiyokawa N, Kato M, et al. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan. *Blood Cancer J.* 2016;6(5):e419.
45. Reshmi SC, Harvey RC, Roberts KG, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. *Blood.* 2017;129(25):3352-3361.
46. Zenatti PP, Ribeiro D, Li W, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. *Nat Genet.* 2011;43(10):932-939.
47. Neumann M, Vosberg S, Schlee C, et al. Mutational spectrum of adult T-ALL. *Oncotarget.* 2015;6(5):2754-2766.
48. Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and molecular biology of T-ALL. *Blood.* 2017;129(9):1113-1123.
49. Liu Y, Easton J, Shao Y, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nat Genet.* 2017;49(8):1211-1218.
50. Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition [published correction appears in *Blood* 2015;125(5):890]. *Blood.* 2014;124(23):3420-3430.
51. Kerstjens M, Driessen EM, Willekes M, et al. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations. *Oncotarget.* 2017;8(9):14835-14846.
52. Jerchel IS, Hoogkamer AQ, Ariès IM, et al. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. *Leukemia.* 2018;32(4):931-940.
53. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. *Blood.* 2005;105(2):812-820.
54. Harvey RC, Kang H, Roberts KG, et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like signature ("Ph-like" or "BCR-ABL1-Like") for therapeutic targeting and clinical intervention. *Blood.* 2013;122(21):826.
55. Kang H, Chen IM, Wilson CS, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. *Blood.* 2010;115(7):1394-1405.
56. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. *J Clin Oncol.* 2009;27(31):5175-5181.
57. Schultz KR, Carroll A, Heerema NA, et al; Children's Oncology Group. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. *Leukemia.* 2014;28(7):1467-1471.
58. Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children's Oncology Group Trial AALL0622. *J Clin Oncol.* 2018;36(22):2306-2314.

59. Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. *Proc Natl Acad Sci USA*. 2010;107(1):252-257.
60. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*. 2012;119(15):3512-3522.
61. He J, Abdel-Wahab O, Nahas MK, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. *Blood*. 2016;127(24):3004-3014.
62. Akhter A, Mughal MK, Elyamany G, et al. Multiplexed automated digital quantification of fusion transcripts: comparative study with fluorescent in-situ hybridization (FISH) technique in acute leukemia patients. *Diagn Pathol*. 2016;11(1):89.
63. Afrin S, Zhang CRC, Meyer C, et al. Targeted next-generation sequencing for detecting *MLL* gene fusions in leukemia. *Mol Cancer Res*. 2018;16(2):279-285.
64. Loh ML, Zhang J, Harvey RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. *Blood*. 2013;121(3):485-488.
65. Foà R, Vitale A, Vignetti M, et al; GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood*. 2011;118(25):6521-6528.
66. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. *Lancet Oncol*. 2012;13(9):936-945.
67. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. *Blood*. 2014;123(6):843-850.
68. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. *J Clin Oncol*. 2013;31(25):e413-e416.
69. Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. *Haematologica*. 2013;98(11):e146-e148.
70. Kobayashi K, Miyagawa N, Mitsui K, et al. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. *Pediatr Blood Cancer*. 2015;62(6):1058-1060.
71. Jain N, Jabbour EJ, McKay PZ, et al. Ruxolitinib or dasatinib in combination with chemotherapy for patients with relapsed/refractory Philadelphia (Ph)-like acute lymphoblastic leukemia: a phase I-II trial. *Blood*. 2017;130(suppl 1):1322.
72. Tasian SK, Teachey DT, Li Y, et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. *Blood*. 2017;129(2):177-187.
73. Wu SC, Li LS, Kopp N, et al. Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia. *Cancer Cell*. 2015;28(1):29-41.
74. Suryani S, Bracken LS, Harvey RC, et al. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. *Mol Cancer Ther*. 2015;14(2):364-374.
75. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases [published correction appears in *Nat Rev Drug Discov*. 2017;17(1):78]. *Nat Rev Drug Discov*. 2017;16(12):843-862.
76. Senkevitch E, Durum S. The promise of Janus kinase inhibitors in the treatment of hematological malignancies. *Cytokine*. 2017;98:33-41.
77. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. *Blood*. 2010;115(15):3109-3117.
78. Loh ML, Tasian SK, Rabin KR, et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children's Oncology Group phase 1 consortium study (ADVL1011). *Pediatr Blood Cancer*. 2015;62(10):1717-1724.
79. Tasian SK, Assad A, Hunter DS, Du Y, Loh ML. A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269/AALL1521): dose-finding results from the part 1 safety phase. *Blood*. 2018;132(suppl 1):555.
80. Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. *J Clin Oncol*. 2016;34(20):2380-2388.
81. Curran E, Stock W. How I treat acute lymphoblastic leukemia in older adolescents and young adults [published correction appears in *Blood*. 2015;126(15):1868]. *Blood*. 2015;125(24):3702-3710.
82. Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. *Blood*. 2019;133(14):1548-1559.
83. Bugarin C, Sarno J, Palmi C, et al; I-BFM study group. Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. *Haematologica*. 2015;100(6):e229-e232.
84. Russell LJ, Enshaei A, Jones L, et al. IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. *J Clin Oncol*. 2014;32(14):1453-1462.